Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | EBP | Q15125 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13730581 | 0.83 | GBA1 (0.41) | MAPT | |
| SCHEMBL13730672 | 0.82 | EPAS1 (0.38) | — | |
| SCHEMBL13731094 | 0.79 | LOX (0.39) | — | |
| SCHEMBL29655157 | 0.77 | NR1H2 (0.34) | — | |
| SCHEMBL13732231 | 0.77 | ALDH1A1 (0.39) | — | |
| Mesdopetam SCHEMBL29438808 | 0.76 | KAT6A (0.40) | TSHR | |
| Mesdopetam SCHEMBL13732678 | 0.76 | KAT6A (0.40) | TSHR | |
| Mesdopetam SCHEMBL29438806 | 0.76 | KAT6A (0.40) | TSHR | |
| SCHEMBL25405123 | 0.75 | EPAS1 (0.37) | — | |
| SCHEMBL30807872 | 0.75 | GBA1 (0.41) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2699543-B1 | NOVEL MODULATORS OF CORTICAL DOPAMINERGIC- AND NMDA-RECEPTOR-MEDIATED GLUTAMATERGIC NEUROTRANSMISSION | INTEGRATIVE RES LAB SWEDEN AB (SE) | 2016-03-02 | — | — | EP | claimed |
| US-9006227-B2 | Modulators of cortical dopaminergic- and NMDA-receptor-mediated glutamatergic neurotransmission | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) | 2015-04-14 | — | — | US | claimed |
| US-20140128360-A1 | NOVEL MODULATORS OF CORTICAL DOPAMINERGIC- AND NMDA-RECEPTOR-MEDIATED GLUTAMATERGIC NEUROTRANSMISSION | Integrative Research Laboratories Swenden AB (SE) | 2014-05-08 | — | — | US | claimed |
| EP-2699543-A1 | NOVEL MODULATORS OF CORTICAL DOPAMINERGIC- AND NMDA-RECEPTOR-MEDIATED GLUTAMATERGIC NEUROTRANSMISSION | Integrative Research Laboratories Sweden AB (SE) | 2014-02-26 | — | — | EP | claimed |
| WO-2012143337-A1 | NOVEL MODULATORS OF CORTICAL DOPAMINERGIC- AND NMDA-RECEPTOR-MEDIATED GLUTAMATERGIC NEUROTRANSMISSION | NEUROSEARCH A/S (DK) | 2012-10-26 | — | — | WO | claimed |
| EP-2699543-B1 | NOVEL MODULATORS OF CORTICAL DOPAMINERGIC- AND NMDA-RECEPTOR-MEDIATED GLUTAMATERGIC NEUROTRANSMISSION | INTEGRATIVE RES LAB SWEDEN AB (SE) | 2016-03-02 | — | — | EP | disclosed |
| US-9120728-B2 | Modulators of cortical dopaminergic- and NMDA-receptor-mediated glutamatergic neurotransmission | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) | 2015-09-01 | — | — | US | disclosed |
| US-20150148426-A1 | NOVEL MODULATORS OF CORTICAL DOPAMINERGIC- AND NMDA-RECEPTOR-MEDIATED GLUTAMATERGIC NEUROTRANSMISSION | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) | 2015-05-28 | — | — | US | disclosed |
| US-9006227-B2 | Modulators of cortical dopaminergic- and NMDA-receptor-mediated glutamatergic neurotransmission | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) | 2015-04-14 | — | — | US | disclosed |
| US-20140128360-A1 | NOVEL MODULATORS OF CORTICAL DOPAMINERGIC- AND NMDA-RECEPTOR-MEDIATED GLUTAMATERGIC NEUROTRANSMISSION | Integrative Research Laboratories Swenden AB (SE) | 2014-05-08 | — | — | US | disclosed |
| EP-2699543-A1 | NOVEL MODULATORS OF CORTICAL DOPAMINERGIC- AND NMDA-RECEPTOR-MEDIATED GLUTAMATERGIC NEUROTRANSMISSION | Integrative Research Laboratories Sweden AB (SE) | 2014-02-26 | — | — | EP | disclosed |
| WO-2012143337-A1 | NOVEL MODULATORS OF CORTICAL DOPAMINERGIC- AND NMDA-RECEPTOR-MEDIATED GLUTAMATERGIC NEUROTRANSMISSION | NEUROSEARCH A/S (DK) | 2012-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128360-A1 | NOVEL MODULATORS OF CORTICAL DOPAMINERGIC- AND NMDA-RECEPTOR-MEDIATED GLUTAMATERGIC NEUROTRANSMISSION | GRIN3A, GRIN1, GRIN3B | MAPT 608/4885CHRNA7 42/4885KMT2A 639/4885 |
| US-20150148426-A1 | NOVEL MODULATORS OF CORTICAL DOPAMINERGIC- AND NMDA-RECEPTOR-MEDIATED GLUTAMATERGIC NEUROTRANSMISSION | GRIN3A, GRIN1, GRIN3B | MAPT 608/4885CHRNA7 42/4885KMT2A 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.